Orludodstat (BAY 2402234)

Catalog No.S8847 Batch:S884701

Print

Technical Data

Formula

C21H18ClF5N4O4
Molecular Weight 520.84 CAS No. 2225819-06-5
Solubility (25°C)* In vitro DMSO 100 mg/mL (191.99 mM)
Ethanol 33 mg/mL (63.35 mM)
Water Insoluble
In vivo (Add solvents to the product individually and in order)
Clear solution
5%DMSO 40%PEG300 5%Tween80 50%ddH2O
5.0mg/ml Taking the 1 mL working solution as an example, add 50 μL of 100 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to make it clear; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results. 
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description Orludodstat (BAY 2402234) is a novel and selective dihydroorotate dehydrogenase (DHODH) inhibitor with an IC50 of 1.2 nM.
Targets
DHODH [1]
(Cell-free assay)
1.2 nM
In vitro

BAY 2402234 induces differentiation and inhibits proliferation in AML cell lines across multiple AML subtypes.[1]
In vivo

BAY 2402234 shows strong monotherapy efficacy and induces differentiation in AML xenograft models in vivo.[1]

Protocol (from reference)

Cell Assay:

[1]
  • Cell lines

    MOLM-13, HEL, MV4-11, SKM-1 and THP-1 cell lines

  • Concentrations

    0.1nM to 1μM

  • Incubation Time

    96 h

  • Method

    MOLM-13, HEL, MV4-11, SKM-1 and THP-1 cells were plated in 96-well plates at 20,000 cells per well in their respective growth media and were treated with BAY 2402234 in the presence or absence of 100 μM uridine.
Animal Study:

[2]
  • Animal Models

    Female ICR SCID mice

  • Dosages

    4 mg/kg

  • Administration

    p.o.

Selleck's Orludodstat (BAY 2402234) has been cited by 4 publications

Identification of dihydroorotate dehydrogenase inhibitor, vidofludimus, as a potent and novel inhibitor for influenza virus [ J Med Virol, 2024, 96(1):e29372] PubMed: 38235544
Inhibitors of dihydroorotate dehydrogenase cooperate with molnupiravir and N4-hydroxycytidine to suppress SARS-CoV-2 replication [ iScience, 2022, 25(5):104293] PubMed: 35492218
N4-hydroxycytidine and inhibitors of dihydroorotate dehydrogenase synergistically suppress SARS-CoV-2 replication [ bioRxiv, 2021, 10.1101/2021.06.28.450163] PubMed: N/A
N4-hydroxycytidine and inhibitors of dihydroorotate dehydrogenase synergistically suppress SARS-CoV-2 replication [ bioRxiv, 2021, 10.1101/2021.06.28.450163] PubMed: None

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.